Scarica l'app Stockscreener
80.30
1.52%
-1.24
Dopo l'orario di chiusura:
80.49
0.19
+0.24%
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
How resilient is Ionis Pharmaceuticals Inc. stock in market downturns2025 Price Action Summary & Weekly Stock Breakout Alerts - ulpravda.ru
Will Ionis Pharmaceuticals Inc. (ISI) stock benefit from infrastructure billEarnings Recap Report & Accurate Buy Signal Alerts - ulpravda.ru
Momentum Shift: Will Ionis Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - ulpravda.ru
Will Ionis Pharmaceuticals Inc. stock recover faster than peersEntry Point & Daily Risk Controlled Trade Plans - ulpravda.ru
Book value per share of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView — Track All Markets
How Ionis Pharmaceuticals Inc. stock compares to industry benchmarksGap Down & Technical Pattern Based Buy Signals - ulpravda.ru
Can Ionis Pharmaceuticals Inc. stock sustain market leadershipTrade Entry Summary & Community Consensus Picks - ulpravda.ru
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - Nasdaq
Sentiment Review: Why Ionis Pharmaceuticals Inc. stock could see breakout soon - ulpravda.ru
Why Ionis Pharmaceuticals Inc. stock is a value investor pickTrade Exit Report & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
Ionis Pharmaceuticals stock hits 52-week high at 83.62 USD By Investing.com - Investing.com Nigeria
Why Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 Goals And What's Next - Yahoo Finance
GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B - MedCity News
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Benzinga
GSK, Ionis claim study success for RNA-based hepatitis B drug - BioPharma Dive
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Hepatitis B Market to Witness Promising Upswing by 2034, - openPR.com
GSK Scores An R&D Win With Bepirovirsen Phase III Hep B Data - Citeline News & Insights
Ionis Pharmaceuticals Announces Positive Phase 3 Results for Bepirovirsen - TradingView — Track All Markets
GSK’s hepatitis B drug shows positive results in phase 3 trials - Investing.com Canada
New hepatitis B drug delivers functional cures in major global trial - Stock Titan
Ionis Pharmaceuticals Inc Stock Analysis and ForecastEarnings Volatility Patterns & Budget Friendly Capital Growth - earlytimes.in
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies - Bitget
Ionis Pharmaceuticals EVP Research Sells Shares - TradingView — Track All Markets
Treatment-resistant Hypertension Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics - Barchart.com
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Nucleic Acid Therapeutics Market to Reach US$ 14.42 Billion - openPR.com
Assessing Ionis Pharmaceuticals (IONS) Valuation After Analyst Optimism And FDA Approval Of Tryngolza - Sahm
Wells Fargo Raises Price Target for Ionis Pharmaceuticals (IONS) to $100 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring A 10.44% Upside Potential - DirectorsTalk Interviews
Ionis Pharmaceuticals (LTS:0JDI) EV-to-FCF : -39.27 (As of Jan. 05, 2026) - GuruFocus
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN
Stock Traders Buy High Volume of Ionis Pharmaceuticals Call Options (NASDAQ:IONS) - MarketBeat
Diversified Trust Co Invests $1.02 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Death Cross: Can Ionis Pharmaceuticals Inc stock continue upward trendMarket Movers & Reliable Breakout Forecasts - moha.gov.vn
Revenues Not Telling The Story For Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - 富途牛牛
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
162,800 Shares in Ionis Pharmaceuticals, Inc. $IONS Bought by Capricorn Fund Managers Ltd - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
How Ionis Pharmaceuticals Inc. stock reacts to job market dataJuly 2025 Review & High Accuracy Trade Alerts - ulpravda.ru
Discipline and Rules-Based Execution in IONS Response - news.stocktradersdaily.com
Will Ionis Pharmaceuticals Inc. stock outperform international peers2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Assenagon Asset Management S.A. Boosts Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
cathie wood’s ARK stock trades highlight ionis pharma sale By Investing.com - Investing.com Canada
cathie wood’s ARK stock trades highlight ionis pharma sale - Investing.com
Dip Buying: How Ionis Pharmaceuticals Inc. stock reacts to job market dataFed Meeting & Weekly Top Performers Watchlists - Улправда
Will Ionis Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Snapshot & Safe Swing Trade Setups - DonanımHaber
Can Ionis Pharmaceuticals Inc. stock continue upward trend2025 Growth vs Value & Daily Chart Pattern Signal Reports - DonanımHaber
Is Ionis Pharmaceuticals Inc. stock a safe investment in uncertain marketsForecast Cut & AI Optimized Trading Strategy Guides - Улправда
Ionis Pharmaceuticals Inc (HAM:ISI) Competitors 2025 - GuruFocus
Ionis Pharmaceuticals Inc Stock Operating Data - GuruFocus
Why retail investors favor Ionis Pharmaceuticals Inc. stockWeekly Risk Summary & Safe Entry Point Identification - Улправда
RBC Capital Maintains Ionis Pharmaceuticals (IONS) Outperform Recommendation - Nasdaq
How reliable is Ionis Pharmaceuticals Inc. (ISI) stock dividend growthStock Buyback Updates & Learn the Basics of Investing in 5 Days - Bollywood Helpline
RBC Capital Raises Price Target for Ionis Pharmaceuticals (IONS) to $95 | IONS Stock News - GuruFocus
RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating - marketscreener.com
Sicart Associates LLC Has $10.75 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals stock price target raised to $95 from $82 at RBC Capital - Investing.com UK
EBITDA per share of Ionis Pharmaceuticals, Inc. – TRADEGATE:ISI - TradingView — Track All Markets
Ionis Pharmaceuticals (IONS): Leerink Partners Raises Price Targ - GuruFocus
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):